Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

Journal of hepatology - 1 Jan 2012

Kumada Hiromitsu, Toyota Joji, Okanoue Takeshi, Chayama Kazuaki, Tsubouchi Hirohito, Hayashi Norio

Abstract excerpt

BACKGROUND & AIMS: To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C. METHODS: In a multi-center randomized clinical trial in Japan, on patients infected with HCV of genotype 1, 126 patients were assigned to telaprevir for 12 weeks along with PEG-IFN and RBV for 24 weeks (Group A), while 63 to PEG-IFN and RBV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Eruptions
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Diseases

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 21827730
DOI: 10.1016/j.jhep.2011.07.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.PMID 21827730Read ↗

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.Semantic proximity Read ↗

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.Semantic proximity Read ↗

Hepatitis C therapy update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.